DOCSLIB.ORG

Immunoadsorption Therapy for Myasthenia Gravis J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.57.5.578 on 1 May 1994

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunoadsorption Therapy for Myasthenia Gravis J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.57.5.578 on 1 May 1994 57858ournal ofNeurology, Neurosurgery, and Psychiatry 1994;57:578-581 Immunoadsorption therapy for myasthenia gravis J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.57.5.578 on 1 May 1994. Downloaded from Noritoshi Shibuya, Takeshi Sato, Mitsuhiro Osame, Toshihiko Takegami, Shizuki Doi, Sachiko Kawanami Abstract neurological disorders. A major disadvantage The results of a multicentre trial were of currently available plasma exchange proce- analysed to evaluate the efficacy of dures is the non-selective removal of essential immunoadsorption therapy for severe plasma components, necessitating a supply of generalised myasthenia gravis. Twenty plasma products to serve as a substitute fluid. patients with myasthenia gravis who were Plasma exchange is costly and carries serious concurrently receiving high dose pred- risks of anaphylactic reactions and viral infec- nisolone and azathioprine therapy were tions.6 9 10 It is preferable to remove pathogenic treated with an affinity-type adsorbent, substances from the circulation selectively. A using tryptophan-linked polyvinyl alco- specially designed affinity-type immunoadsor- hol gel (IM-TR), according to a standard- bent to selectively remove AChR antibodies ised treatment protocol. The 20 patients has been developed."' 12 This material is a syn- received five adsorption treatments within thetic resin consisting of tryptophan-linked a period of 10 days. In 11, pronounced polyvinyl alcohol gel (IM-TR). It adsorbs a improvement of myasthenic weakness large number of the AChR antibodies through was seen and long-term remission was hydrophobic interaction and rapidly improves maintained. The treatment was espe- myasthenic weakness.13'6 cially effective in patients with thymic The present study was carried out at six hyperplasia. Circulating acetylcholine neurological hospitals, according to a stan- receptor (AChR) antibodies were dardised treatment protocol to assess the clin- reduced by about 60% by treating one ical usefulness of IM-TR therapy in cases of plasma volume. There was no difference severe myasthenia gravis. in the rate of removal of the AChR anti- bodies between patients with thymic hyperplasia and patients with thymoma. Patients and methods Department of included in this study had severe gen- Neurology, Kawatana No serious complications occurred dur- Patients National Hospital, ing 100 procedures. It was concluded that eralised myasthenia gravis diagnosed by typi- Nagasaki, Japan the inmunoadsorption therapy with IM- cal clinical signs and raised titres of antibodies N Shibuya TR is useful in controlling symptoms in to AChR (more than 0-5 nmol/l bungarotoxin Department of patients with severe myasthenia gravis binding); patients were in myasthenic crisis http://jnnp.bmj.com/ Neurology, Juntendo University, Tokyo, who are otherwise unresponsive. with rapid deterioration within less than two Japan weeks. Criteria for exclusion were chronic T Sato (7 Neurol Neurosurg Psychiatry 1994;57:578-581) severe and stable myasthenia gravis; multiple Third Department of changes in the immunosuppressive medica- Internal Medicine, tion before treatment; and malignant (inva- Kagoshima University, Circulating antibodies to the acetylcholine sive) thymoma as determined by a are in serum in diagnosis of the thymus gland. Kagoshima, Japan receptor (AChR) detectable pathological on September 27, 2021 by guest. Protected copyright. M Osame 85%-90% of patients with generalised myas- Twenty patients, range 15-65 years (five Department of thenia gravis.'-3 Most AChR antibodies in IgG men, 20 women), have been treated with the Neurol6gy, Nagoya were acetyl- National Hospital, bind to the main immunogenic region of the a immunoadsorption. All receiving Aichi, Japan subunit of the AChR, and cause AChR degra- cholinesterase inhibitors. The dose was kept T Takegami dation secondary to cross-linking and modu- constant during the study. All patients had to Department of lation.2-5 Plasma exchange has been shown to have undergone thymectomy at least three Neurology, Sapporo induce a recovery from myasthenic months before the study. Their thymic histol- Minami National rapid Hospital, Hokkaido, weakness in association with the decline of the ogy showed thymic hyperplasia in 13, thy- Japan AChR antibodies." At a consensus develop- moma in six, and was indeterminate in one S Doi ment conference, plasma exchange was con- (table 1). The histological diagnoses were First Department of sidered effective in the management of certain obtained from the surgical pathologists' Internal Medicine, Fukuoka University, Fukuoka, Japan Table 1 Analysis of relation between clinicalfeatures and outcome ofimmunoadsorption therapy Kawanami S Removal of Correspondence to: Sex Duration Time before Thymic histology* AChR Ab Dr N Shibuya, Departnent No of ofillness thymectomy on day 10 of Neurology, Kawatana patients Age M F (y) (y) Hyperplasia Thymoma (%) National Hospital, 2005-1 Effect Shimogumigo, Kawatana, Pronounced 11 40(13) 2 9 9(5) 4(3) 9 1 58(9) Higashisonogi-gun, Poor and 9 36(17) 3 6 5(5) 3(4) 4 5 65(14) Nagasaki, 859-36 Japan. unresponsive Received 13 April 1993 p Value NS NS NS NS <0 05 NS and in revised form 7 June 1993. Values are means (SD); NS = non-significant; p values are one-tailed. Accepted 14 July 1993 *Thymic histology was unknown in one patient. Immunoadsorption therapyfor myasthenia gravis 579 reports. The thymoma were of both lympho- laboratory findings were obtained at 0, 4, 11, J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.57.5.578 on 1 May 1994. Downloaded from cytic and epithelial types. In the non-tumour 14, and 28 days according to the study proto- cases the thymus showed hyperplasia of col. The observation period was extended up lymph follicles. to 42 days if no change in the treatment had Immunosuppressive treatment with aza- occurred. The effects of immunoadsorption thioprine and prednisolone was instituted on were also analysed in relation to clinical fea- day 0. Azathioprine was given at a dose of 3 tures such as age, sex, duration of illness, time mg/kg body weight during the first week and before thymectomy, and thymic histology. 2-5-2 mg/kg body weight for the subsequent The clinical and electrophysiological exam- four weeks (if this dose was not tolerated it inations were performed by the local neuro- was reduced to 2-1P5 mg/kg body weight). logical investigator. The examining Prednisolone was given at a dose of 1-5 mg/kg neurologists were blind as to plasma exchange body weight for the first two weeks, and treatments. All laboratory investigations that 1 5 mg/kg body weight on alternate days would allow the neurological investigator to thereafter. know about the treatment were kept separate Immunoadsorption with IM-TR was car- and were only known to the physician per- ried out on-line with a plasma separator con- forming plasma exchange. Raw data were sisting of a cellulose diacetate membrane. The listed in the study protocol and sent to the blood flow was kept at 70-80 ml/min, and study coordinator for statistical analysis. the transmembrane pressure was less than Because this study was designed as an 40 mm Hg. The flux rate of the filtration (the open, one-armed treatment trial, all compar- flow rate at the IM-TR column) was 20 isons were within groups. Changes from base- ml/min. Adsorption was performed with line observed at 11 days and 28 days after about one plasma volume (an average of 2300 treatment were also compared to analyse the ml of plasma) on days 1, 3, 5, 8, and 10, for a time profile, because the main response vari- total of five treatments. Heparin was used as able in evaluating efficacy was the change in an anticoagulant at an initial dose of 2000 the clinical scores adjusted by the pre-treat- units, then 2000 units/hour during the period ment value. The baseline employed was the of perfusion. Fluids contained in the system observation immediately before the first were reinfused into the patient at the end of immunoadsorption treatment. Statistical the procedure. No plasma proteins were analysis was by Student's t test or x2 test. given. Results are expressed as means (SD). Clinical assessment was based on clinical muscle testing (the myasthenia gravis score of Besinger and Toyka17), the titre of antibodies Results to AChR (a standard immunoprecipitation Pronounced and rapid recovery from myas- assay with solubilised human receptor'), elec- thenic weakness was noted in 11 patients after tromyographic analysis of the neuromuscular a series of immunoadsorption treatments, but transmission block, and side effects if any. in the others the clinical state showed little Briefly, a four-step system for grading muscle change despite a substantial dectease in strength was used (ranging from 0 = normal AChR antibody titre (table 1). Nine of 13 http://jnnp.bmj.com/ to 3 = severe weakness). In each patient, five patients with thymic hyperplasia improved, test items for muscles of the limbs and trunk although only one of six patients with thy- and three test items for the oropharyngeal moma benefited (table 1). The improvement muscles were examined. All items were given was stable in nine of them for at least 32 days the same weight. The myasthenia gravis score after termination of the immunoadsorption. was calculated as the sum of the grades in The clinical effect was significantly correlated each item divided by the number of the items with thymic histology (tables 1 and 2), but no tested. For each patient, the treatment was correlation was noted with age, sex, duration on September 27, 2021 by guest. Protected copyright. judged to be efficacious if the myasthenia of illness, and time before thymectomy (table gravis score on day 11 was more than 35% 1). Percentage improvement of the mean higher than the pretreatment value. To esti- myasthenia gravis score was 39% on day 1 1 mate the neuromuscular transmission block and 35% on day 28 in patients with thymic quantitatively, the decline in the amplitude of hyperplasia, whereas it was 15% and 1 % in successive responses to repetitive nerve stimu- those with thymoma (table 2).
Load more

Recommended publications
  • Severe Asthma Associated with Myasthenia Gravis and Upper Airway Obstruction a Souza-Machado,1,2 E Ponte,2 ÁA Cruz2
    Severe Asthma and Myasthenia Gravis CASE REPORT Severe Asthma Associated With Myasthenia Gravis and Upper Airway Obstruction A Souza-Machado,1,2 E Ponte,2 ÁA Cruz2 1Pharmacology Department, Bahia School of Medicine and Public Health, Universidade Federal da Bahia, Salvador–Bahia, Brazil 2Asthma and Allergic Rhinitis Control Program (ProAR), Bahia Faculty of Medicine, Universidade Federal da Bahia, Salvador–Bahia, Brazil ■ Abstract An unusual association of asthma and myasthenia gravis (MG) complicated by tracheal stenosis is reported. The patient was a 35-year-old black woman with a history of severe asthma and rhinitis over 30 years. A respiratory tract infection triggered a life-threatening asthma attack whose treatment required orotracheal intubation and mechanical ventilatory support. A few weeks later, tracheal stenosis was diagnosed. Clinical manifestations of MG presented 3 years after her near-fatal asthma attack. Spirometry showed severe obstruction with no response after inhalation of 400 µg of albuterol. Baseline lung function parameters were forced vital capacity, 3.29 L (105% predicted); forced expiratory volume in 1 second (FEV1), 1.10 L (41% predicted); maximal midexpiratory fl ow rate, 0.81 L/min (26% predicted). FEV1 after administration of albuterol was 0.87 L (32% predicted). The patient’s fl ow–volume loops showed fl attened inspiratory and expiratory limbs, consistent with fi xed extrathoracic airway obstruction. Chest computed tomography scans showed severe concentric reduction of the lumen of the upper thoracic trachea. Key words: Asthma. Tracheal stenosis. Myasthenia gravis. Exacerbation. ■ Resumen En este caso informamos de una asociación infrecuente entre el asma y la miastenia grave (MG) complicada por estenosis traqueal.
    [Show full text]
  • Invasive Aspergillosis Poster IDSA FINAL Pdf.Pdf
    Invasive Aspergillosis Associated with Severe Influenza Infections Nancy Crum-Cianflone MD MPH Scripps Mercy Hospital, San Diego, CA USA Abstract Background (cont.) Results Results (cont.) Background: Bacterial superinfections are well-described complications of influenza • Typically, invasive aspergillosis occurs among severely immunosuppressed hosts Case-Control Study • Systematic Review of the Literature infection, however few data exist on invasive fungal infections in this setting. The Hematologic malignancies, neutropenia, and transplant recipients 48 medical ICU patients underwent influenza testing; 8 were diagnosed with influenza N=52 and present cases (n=5) = 57 total cases • All influenza-positive patients had ventilator-dependent respiratory failure A summary of the cases is shown in Table 2 pathogenesis of invasive aspergillosis may be related to respiratory epithelium • Isolation of Aspergillus sp. in the immunocompetent host without these conditions may be initially considered as a colonizer or non-pathogen Of the 8 patients with severe influenza infection, six (75%) had Aspergillus sp. isolated Increasing number of cases over time: disruption and viral-induced lymphopenia. • 4 A. fumigatus, 1 A. fumigatus and A. versicolor, and 1 A. niger isolated • First cases described in 1979, followed by three cases in the 1980s, two cases in the 1990s, two cases in • However, recent cases have suggested that Aspergillus may rapidly lead to invasive • Since A. niger was of unknown pathogenicity this case was excluded the 2000’s, and 48 cases from 2010 to the 1st quarter of 2016 demonstrating an increasing trend of aspergillosis superinfection (p<0.001) Methods: A retrospective study was conducted among severe influenza cases requiring disease in the setting of severe influenza infection [2,3] Of the 40 patients negative for influenza admitted to the same ICU, none had Aspergillus ICU admission at a large academic hospital (2015-2016).
    [Show full text]
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • Myasthenia Gravis
    FACT SHEET FOR PATIENTS AND FAMILIES Myasthenia Gravis What is myasthenia gravis? How is it diagnosed? Myasthenia [mahy-uh s-THEE-nee-uh] gravis is a disease Your doctor will ask you about your symptoms, where the body’s immune system attacks the perform a physical examination, and review all of connection between the nerve and muscle, causing your blood work and other tests. More blood work weakness. might be ordered to look for signs that the immune system might be attacking the muscles. A doctor may What causes it? What are the risk also perform a nerve conduction study known as factors? electromyography [ih-lek-troh-mahy-OG-ruh-fee} or EMG. Myasthenia gravis is an autoimmune [aw-toh-i-MYOON] An EMG records the electrical activity of muscles. disease. It occurs when the parts of the immune system that normally attack bacteria and viruses What are the complications? (antibodies) accidentally attack the connection If symptoms become severe, you may not be able between the nerve and muscle, also known as the to breathe normally or swallow saliva or food. This neuromuscular [noor-oh-MUHS-kyuh-ler] junction. results in aspiration [as-puh-REY-shuh n], where food or saliva goes into your airway. Serious complications The antibodies block a chemical called acetylcholine like these can result in injury or even death if left [uh-seet-l-KOH-leen], which is released by the nerve untreated. ending to activate the muscle, creating movement. Blocking this chemical causes weakness. How is it treated? Risk factors for myasthenia gravis include having a Mild symptoms are treated with a medicine called personal or family history of autoimmune diseases.
    [Show full text]
  • Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
    Journal ofNeurology, Neurosurgery, and Psychiatry, 1972, 35, 385-394 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.35.3.385 on 1 June 1972. Downloaded from Multiple sclerosis associated with defects in neuromuscular transmission BERNARD M. PATTEN, AVERY HART, AND ROBERT LOVELACE' From The Neurological Clinical Research Center, Department ofNeurology, College ofPhysicians andSurgeons, Columbia University, New York City, U.S.A. SUMMARY Three patients with multiple sclerosis characterized by exacerbations and remissions of nervous system signs and symptoms disseminated in time and space also had the kind of easy fatigu- ability seen in myasthenia gravis. In each case abnormal decrements to repetitive stimulation were electromyographically demonstrated and treatment with ephedrine or anticholinesterase drugs increased the patient's functional capacity while improving the electromyographic abnormality. The suggestion is that these patients represent an overlap syndrome, analogous to the overlap syndrome existing between systemic lupus erythematosus and rheumatoid arthritis where clinical and laboratory features of two diseases coexist in the same patient at the same time. Presumably some patients with multiple sclerosis have deficient production of acetylcholine, just like patients with myasthenia, and treatment with agents useful in myasthenia is able partially to correct the the The cases illustrate how in neurology greater attention to the symptoms caused by deficiency. Protected by copyright. more immediate cause of clinical
    [Show full text]
  • The Rare Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis in a 17-Year-Old Female
    Bahrain Medical Bulletin, Vol. 42, No. 3, September 2020 The Rare Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis in a 17-Year-Old Female Ali Alsada, BSc, MD* Basem Mustafa, MBBS, MRCP** Systemic Lupus Erythematosus (SLE) and Myasthenia Gravis (MG) are two distinct diseases, which can coexist or precede each other; however, their occurrence in the same patient is rare. This rare phenomenon has already been observed; however, only sporadic clinical cases have been described. A seventeen-year-old female who is a known case of SLE developed MG years later. Nerve conduction studies showed the decremental response over facial muscles and right median nerve. Anti-acetylcholine receptor (AChR) antibodies were positive. She was treated with oral pyridostigmine 60 mg three times a day. Clinical improvement and resolve of muscular weakness was seen within a couple of days. The patient was discharged on prednisolone 10 mg OD and pyridostigmine 60 mg TDS. Bahrain Med Bull 2020; 42 (3): 224 - 225 Systemic Lupus Erythematosus (SLE) is an autoimmune disease noticed sometimes, especially on repeated movements but there with multi-organ involvement of unknown etiology, in which was no diplopia. there is an inter-play of genetic, epigenetic and environmental factors1. It is not uncommon to find more than one autoimmune Her investigations revealed normal CBC, ESR, RFT, LFT, CK, disease in the same patient2. It has been described that SLE LDH and TSH. Thyroglobulin and smooth muscle antibodies patients can have Primary Sjogren’s Syndrome (PSS), Systemic were negative. CXR and ECG were normal. HRCT was Sclerosis (SS), Hashimoto’s Thyroiditis (HT), Myasthenia normal with no evidence of interstitial lung disease and no Gravis (MG), Polymyositis (PM) and many other autoimmune thymoma.
    [Show full text]
  • Myasthenia Gravis
    A Guide for Patients and Families What is... Myasthenia Gravis Myasthenia gravis (MG) is a chronic autoimmune MG is not inherited, and it is not contagious. Although disease — a disease that occurs when the immune MG is not hereditary, genetic susceptibility appears to system mistakenly attacks the body’s own tissues. play a role in it. Occasionally, the disease may occur in more than one member of the same family. In MG, the immune system attacks and interrupts the connection between nerve and muscle, called the MG causes weakness in muscles that control the neuromuscular junction (NMJ). This causes weakness eyes, face, neck, and limbs. Symptoms include partial in the skeletal muscles, which are responsible for paralysis of eye movements, double vision, and droopy breathing and moving parts of the body. eyelids, as well as weakness and fatigue in neck and jaws with problems in chewing, swallowing, and holding In most cases of MG, the immune system targets the up the head. acetylcholine receptor — a protein on muscle cells that is required for muscle contraction. Muscle weakness in MG gets worse with exertion and improves with rest. About 85 percent of people with MG have antibodies against the acetylcholine receptor in their blood. The Approximately 10-20 percent of people with antibodies target and destroy many of the acetylcholine MG experience at least one myasthenic crisis, an receptors on muscle. Consequently, the muscle’s emergency in which the muscles that control breathing response to repeated nerve signals declines with time, weaken to the point where the individual requires a and the muscles become weak and tired.
    [Show full text]
  • Giant Cell Arteritis Claims Are Costly and Difficult to Defend RONALD W
    Missed diagnoses: a breakdown in communication, coordination, compliance, and situational awareness THE OPHTHALMIC RISK MANAGEMENT OPHTHALMIC MUTUAL INSURANCE COMPANY VOLUME 25 NUMBER 3 2015 Giant cell arteritis claims are costly and difficult to defend RONALD W. PELTON, MD, PhD, OMIC Committee Member, and ANNE M. MENKE, RN, PhD, OMIC Risk Manager 77-year-old male patient When the patient saw the were delayed for so long and presented for the first ophthalmologist about two weeks easy to erroneously conclude that A time to our insured later, he reported a new symptom, both physicians must have been ophthalmologist to report the a low-grade fever, with ongoing incompetent. The claims investigation sudden onset of intermittent diplopia headache and diplopia. Five days showed instead that these physicians six days prior and a headache over after that—a full three weeks after the had treated patients with giant cell his eyebrows for one day. Noting initial visit to the ophthalmologist— arteritis, knew its signs and symptoms right inferior oblique muscle paresis the patient lost vision in his left well, and understood that emergent but unable to determine its cause, eye. An emergency room physician treatment is needed to prevent and with no neuro-ophthalmologist diagnosed giant cell arteritis and imminent, bilateral vision loss. What, in the region, the eye surgeon began intravenous steroid treatment, then, led these physicians astray? referred the patient to a neurologist. but the patient never regained vision Severe vision loss, costly claims The patient told the neurologist in that eye. The malpractice lawsuit that the headache had actually against the ophthalmologist settled for This issue of the Digest will report on lasted for one month and that he $85,000; we do not know the outcome a study of OMIC claims involving 18 was also experiencing jaw pain.
    [Show full text]
  • Myasthenia Associated with Other Autoimmune Diseases: a Series of Cases
    Open Journal of Internal Medicine, 2020, 10, 44-50 https://www.scirp.org/journal/ojim ISSN Online: 2162-5980 ISSN Print: 2162-5972 Myasthenia Associated with Other Autoimmune Diseases: A Series of Cases Boundia Djiba, Nafissatou Diagne, Mohamed Dieng, Baidy Sy Kane, Atoumane Faye, Awa Cheikh Ndao, Maimouna Sow, Abdoulaye Pouye Department of Internal Medicine, Aristide Ledantec Hospital, Dakar, Senegal How to cite this paper: Djiba, B., Diagne, Abstract N., Dieng, M., Kane, B.S., Faye, A., Ndao, A.C., Sow, M. and Pouye, A. (2020) Myas- We report four observations of myasthenia gravis associated with other au- thenia Associated with Other Autoimmune toimmune diseases. Myasthenia gravis can be associated with all autoimmune Diseases: A Series of Cases. Open Journal of diseases with a predominance of dysthyroidism. Among the autoimmune Internal Medicine, 10, 44-50. diseases associated with myasthenia gravis in our series, there were associa- https://doi.org/10.4236/ojim.2020.101005 tions with hyperthyroidism, sjogren syndrome, Biermer’s disease. You would Received: December 3, 2019 have to know how to look for another autoimmune disease in front of all Accepted: February 23, 2020 myasthenia gravis by looking for the slightest sign of appeal that could point Published: February 26, 2020 you towards another pathology. Copyright © 2020 by author(s) and Scientific Research Publishing Inc. Keywords This work is licensed under the Creative Myathenia Gravis, Autoimmun Disease, Association Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access 1. Introduction Myasthenia gravis is defined as an autoimmune disease affecting the neuromus- cular junction.
    [Show full text]
  • Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia
    Standing Council on Health Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition July 2012 Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition July 2012 Disclaimer: Important information about this document This document is not a clinical practice guideline. It intends only to provide information about criteria for accessing intravenous immunoglobulin funded under the National Blood Arrangements. Any advice relating to other forms of treatment relevant to the conditions in The Criteria for the clinical use of intravenous immunoglobulin in Australia (the Criteria) have not been subject to a systematic review and should not be relied upon to guide treatment. Patients and doctors should not use this document as a substitute for expert medical guidance and advice. The relevance and appropriateness of information in this document depends, amongst other things, on an accurate diagnosis, the severity of the condition being properly ascertained, the individual response to diagnostic tests and therapies, and other relevant circumstances in each case. The Criteria was first published in 2007 after a systematic review that was completed in mid-2006. Another systematic review, of a limited number of indications, was then undertaken in 2010-11 to update the Criteria. This review resulted in the addition of a small number of indications, removal of a small number of indications and a rewording of a limited number of indications. Inclusion of indications in the Criteria is based where possible upon systematic review of the evidence. In the absence of published evidence, information and access criteria are based on clinical advice provided to the development group by clinical colleges, clinical societies and individual experts.
    [Show full text]
  • Giant Cell Arteritis Presenting with Superior Oblique Palsy
    Giant Cell Arteritis Presenting with Superior Oblique Palsy First author: Sarah Lopez, O.D. Second author: Mariya Gurvich, O.D. Abstract An 83-year old white male presents with acute intermittent diplopia, decreased vision OD, and symptoms of headache, scalp tenderness, and jaw claudication. Examination reveals right superior oblique palsy. Temporal artery biopsy confirms giant cell arteritis. I. Case History Chief Complaint o An 83-year old white male presents with sudden decreased vision OD and diplopia. Personal Ocular History o Cataracts OU Personal Medical History o Head trauma from fall one month ago o Hypertension o Hyperlipidemia o Congestive heart failure o Abdominal aortic aneurysm o Chronic low back pain Medications o Amlodipine besylate 10 mg o Aspirin 81 mg o Atorvastatin calcium 10 mg o Furosemide 40 mg o Isoniazid 300 mg o Metoprolol succinate 100 mg o Quetiapine fumarate 50 mg o Ranitine HCL 150 mg o Valsartan 80 mg o Prednisone 100 mg II. Pertinent Findings Best-corrected Visual Acuity o OD: 20/40+ OS: 20/40 EOM's: Full OU, right hypertropia in primary gaze, improved with left head tilt Pupils: PERRL, (-) APD Slit Lamp Exam o Anterior segment: 2+ NS OU Goldmann Tonometry: o OD: 17 mmHg OS: 17 mmHg Time: 9:00 am Dilated Fundus Exam o Optic Nerve: distinct margins, pink OU . C/D: 0.25 h/v OU o Macula . Mild ERM OD, clear OS o Vessels: . Normal caliber OU, (-) emboli OU o Periphery: . No holes, tears, breaks 360 OU Laboratory Testing and Imaging o Erythrocyte sedimentation rate: 58 mm/hr (0 - 22 mm/hr) o C-reactive protein: 10.1 mg/L (<10 mg/L) o Platelet count: 393,000 cmm (150,000 - 400,000 cmm) o Fibrinogen: 632 mg/dL (200 - 400 mg/dL) o Lipid profile: Normal o Temporal artery biopsy: Positive o MRI/MRA Brain: Possible focal narrowing of both M1 segments of the middle cerebral arteries.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]